Zydus receives tentative approval from the USFDA for Gabapentin tablets

Zydus receives tentative approval from the USFDA for Gabapentin tablets

The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya

FPJ Web DeskUpdated: Monday, February 20, 2023, 09:52 AM IST
article-image
Zydus receives tentative approval from the USFDA for Gabapentin tablets | Image: Zydus Lifesciences Ltd (Representative)

Zydus Lifesciences Limited’s subsidiary, Zydus Pharmaceuticals (USA) Inc., has received tentative approval from the United States Food and Drug Administration (USFDA) for Gabapentin Tablets, the company said via an exchange filing.

The recommended daily dose is 300 mg or 600 mg (Gralise Tablets).

Gabapentin tablets are indicated for the management of Postherpetic Neuralgia (PHN).

The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya.

Gabapentin Tablets had annual sales of USD 90 mn in the United States (IQVIA MAT Dec. 2022).

The group now has 343 approvals and has so far filed over 440 ANDAs since the commencement of the filing process in FY 2003-04.

RECENT STORIES

First Strikes in 40 Years: Tata Steel Workers in UK to Protest Job Cuts and Furnace Closures

First Strikes in 40 Years: Tata Steel Workers in UK to Protest Job Cuts and Furnace Closures

Morgan Stanley Buys 1.7 Crore Shares Of Axis Bank For ₹2,083 Crore

Morgan Stanley Buys 1.7 Crore Shares Of Axis Bank For ₹2,083 Crore

Infinix Note 40 5G Launched In India With 108MP Camera & 120Hz AMOLED Display

Infinix Note 40 5G Launched In India With 108MP Camera & 120Hz AMOLED Display

Stubborn Food Prices Delaying Disinflation, Says RBI Governor Shaktikanta Das At MPC Minutes

Stubborn Food Prices Delaying Disinflation, Says RBI Governor Shaktikanta Das At MPC Minutes

Paytm To Close THESE Inactive Wallets From July 20: Everything You Need To Know

Paytm To Close THESE Inactive Wallets From July 20: Everything You Need To Know